FDA Poised To Require More Rigorous Study Of Drug Use In Pregnancy
Executive Summary
With new guidance expected, internal comparison groups, better protocols and potential generic industry involvement are some features that appear likely for the next generation of post-marketing requirements to assess drug safety in pregnancy.
You may also be interested in...
Beyond Pregnancy Registries: Complementary Post-Marketing Approaches
New techniques cannot replace registries but can address their limitations, stakeholders tell FDA.
Studying Pregnant Women In Clinical Trials Gaining Industry Support
Once seen as nearly universally forbidden, clinical trial data from the population could make up for failures of post-marketing pregnancy registries to obtain safety information.
Pregnancy Registries May Use External Comparison Groups – Final Guidance
Pregnancy exposure registries may use external comparison groups, including background rates, surveillance systems and other registries, FDA said in its 1pregnancy registry final guidance